Key catalysts approach for Orphazyme, Gemini and Immutep.
The company’s lead cystic fibrosis asset fails, shifting the focus to the Sanofi-partnered Covid-19 vaccine.
The nascent company hopes to prove that its inhaled pan-Jak is best in class.
Astrazeneca and Amgen hope the “totality of the data” will win out for their asthma project.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Galapagos is betting big in IPF but others, including Fibrogen and Roche, are also taking aim at the lung disease.